Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Study shows combining gene therapy and radiation holds promise


A novel approach that combines gene therapy and radiation therapy for treating prostate cancer has shown promising results for its safety and effectiveness, according to Henry Ford Hospital researchers.

The study, published in this month’s edition of Cancer Research, shows that patients experienced no significant side effects when treated with gene therapy and radiation therapy. It also showed that the treatment lowered patients’ prostate-specific antigen (PSA) and eliminated the cancer in many of them.

PSA is a protein produced by the prostate. By measuring its level, doctors can monitor prostate cancer growth as well as the effectiveness of standard and investigational treatments.

All 15 patients enrolled in the study experienced significant declines in their PSA – from an average of 12 to below one – and 10 of them were cancer-free after one year. The patients had an aggressive form of prostate cancer that, if treated with standard radiation therapy alone, would likely recur and possibly spread.

While the results are encouraging, researchers say more research is needed and the novel treatment needs to be tested in a larger randomized clinical trial, which is planned for next year.

"Our belief is that gene therapy could make conventional cancer therapies such as radiation therapy more effective," says Svend Freytag, Ph.D., division head of Henry Ford’s Radiation Oncology Research and lead author of the study.

The study is the first of its kind in the world to test the safety and effectiveness of a replication-competent virus in combination with radiation therapy. The replication-competent virus used in the treatment – the one associated with the common cold – has been shown to enhance the gene therapy’s effectiveness by spreading the gene therapy to nearby cells after it is injected into the prostate.

The virus kills the cancerous cells, but leaves normal ones undamaged. When combined with the gene therapy, it enhances the virus’ effect by rendering the malignant cells sensitive to radiation therapy.

An estimated 220,900 new cases of prostate cancer will be diagnosed this year, and nearly 29,000 men will die of it, according to the American Cancer Society. Prostate cancer is the second-leading cause of cancer death in men, after lung cancer.

Dwight Angell | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>